Table 2.
Placebo (n = 48) |
B. longum APC1472 (n = 74) |
Placebo vs B. Longum APC1472 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Variable | Week 0 | Week 6 | Week 12 | P-value Week 0–12 |
Week 0 | Week 6 | Week 12 | P-value Week 0–12 |
Difference (95% CI) |
P-value | η2 |
Lipid profile | |||||||||||
Cholesterol (mmol/L) |
5.50 ± 0.12 | 5.42 ± 0.13 | 5.34 ± 0.15 | 0.310 | 5.45 ± 0.12 | 5.48 ± 0.12 | 5.41 ± 0.10 | 0.691 | 0.094 (−0.22 to 0.41) |
0.556 | 0.003 |
Triglycerides (mmol/L) |
1.50 ± 0.13 | 1.47 ± 0.11 | 1.41 ± 0.09 | 0.412 | 1.46 ± 0.10 | 1.43 ± 0.08 | 1.49 ± 0.10 | 0.778 | 0.089 (−0.14 to 0.31) |
0.432 | 0.005 |
LDL (mmol/L | 3.72 ± 0.13 | 3.70 ± 0.12 | 3.75 ± 0.15 | 0.896 | 3.73 ± 0.12 | 3.81 ± 0.11 | 3.66 ± 0.10 | 0.473 | −0.083 (−0.38 to 0.21) |
0.579 | 0.003 |
HDL (mmol/L) | 1.33 ± 0.04 | 1.34 ± 0.05 | 1.29 ± 0.05 | 0.537 | 1.29 ± 0.04 | 1.32 ± 0.04 | 1.36 ± 0.04 | 0.039 | 0.091 (−0.01 to 0.19) |
0.074 | 0.027 |
Inflammatory profile | |||||||||||
IL-10 (pg/ml) | 0.43 ± 0.06 | 0.46 ± 0.06 | 0.42 ± 0.05 | 0.696 | 0.36 ± 0.03 | 0.38 ± 0.03 | 0.38 ± 0.05 | 0.807 | −0.012 (−0.15 to 0.13) |
0.864 | <0.001 |
TNF-α (pg/ml) | 1.14 ± 0.10 | 1.18 ± 0.12 | 1.04 ± 0.09 | 0.236 | 0.90 ± 0.06 | 0.88 ± 0.06 | 0.86 ± 0.06 | 0.488 | −0.013 (−0.14 to 0.11) |
0.838 | <0.001 |
IFNγ (pg/ml) | 9.24 ± 1.38 | 9.21 ± 1.11 | 9.6 ± 1.6 | 0.819 | 6.80 ± 0.78 | 5.76 ± 0.50 | 9.4 ± 3.0 | 0.383 | −0.017 (8.29 to 8.26) |
0.997 | <0.001 |